The present invention relates to: a method for producing immunocytes, specifically, induced natural killer T (iNKT) cells that are induced by direct reprogramming of isolated somatic cells, and chimeric antigen receptor (CAR)-iNKT cells into which a CAR gene encoding a CAR is introduced； iNKT cells produced by the method； and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNKT cells. The method according to the present invention can produce, through direct reprogramming, iNKT cells or iNKT cells into which a CAR gene is introduced, from isolated cells so as to simplify the production process and shorten production time so that costs are reduced, have excellent NKT cell production efficiency, and ensure safety according to the production not passing through induced pluripotent stem cells, thereby having an excellent NKT cell production effect differentiated from that of a conventional reprogramming technique. In addition, the iNKT cells or iNKT cells into which a CAR gene is introduced, produced by the method, have an excellent cancer cell killing ability, and thus can be effectively used as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.La présente invention concerne un procédé de production d'immunocytes, plus particulièrement, des cellules tueuses naturelles induites (iNKT) étant induites par une reprogrammation directe de cellules somatiques isolées, et un récepteur d'antigène chimèrique (CAR)-iNKT dans laquelle un gène CAR codant pour un CAR est introduit； des cellules iNKT produites par le procédé； une composition de thérapie cellulaire et une composition pharmaceutique pour prévenir ou traiter le cancer, comprenant les cellules iNKT. Le procédé selon la présente invention peut produire, par reprogrammation directe, des cellules iNKT ou des cellules iNKT dans lesquelles un gène CAR est introduit, à partir de cellules isolées de façon à simplifier le proc
